AI Article Synopsis
- Dengue virus causes about 96 million infections each year, leading to illnesses like dengue fever, and there are currently no medicines to fight it.
- A new powerful drug called JNJ-A07 can block the dengue virus very effectively by stopping two important virus proteins from working together.
- Testing in mice showed that JNJ-A07 can quickly reduce the amount of virus in the body, and researchers are now working on a similar version of this drug.
Article Abstract
Dengue virus causes approximately 96 million symptomatic infections annually, manifesting as dengue fever or occasionally as severe dengue. There are no antiviral agents available to prevent or treat dengue. Here, we describe a highly potent dengue virus inhibitor (JNJ-A07) that exerts nanomolar to picomolar activity against a panel of 21 clinical isolates that represent the natural genetic diversity of known genotypes and serotypes. The molecule has a high barrier to resistance and prevents the formation of the viral replication complex by blocking the interaction between two viral proteins (NS3 and NS4B), thus revealing a previously undescribed mechanism of antiviral action. JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models. Delaying start of treatment until peak viraemia results in a rapid and significant reduction in viral load. An analogue is currently in further development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41586-021-03990-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting the infecting dengue serotype from antibody titre data using machine learning.
PLoS Comput Biol
December 2024
MRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, United Kingdom.
The development of a safe and efficacious vaccine that provides immunity against all four dengue virus serotypes is a priority, and a significant challenge for vaccine development has been defining and measuring serotype-specific outcomes and correlates of protection. The plaque reduction neutralisation test (PRNT) is the gold standard assay for measuring serotype-specific antibodies, but this test cannot differentiate homotypic and heterotypic antibodies and characterising the infection history is challenging. To address this, we present an analysis of pre- and post-infection antibody titres measured using the PRNT, collected from a prospective cohort of Thai children.
View Article and Find Full Text PDFRole of Vigilin and RACK1 in dengue virus- interactions.
mSphere
December 2024
Australian Infectious Disease Research Centre, School of Biological Sciences, The University of Queensland, Brisbane, Queensland, Australia.
Vigilin is a large and evolutionary conserved RNA-binding protein (RBP), which can interact with RNA through its KH domain. Vigilin is, therefore, a multifunctional protein reported to be associated with RNA transport and metabolism, sterol metabolism, chromosome segregation, carcinogenesis, and heterochromatin-mediated gene silencing. The receptor for activated C kinase 1 (RACK1) is another highly conserved protein involved in many cellular pathways.
View Article and Find Full Text PDFSuccessful Management of Severe Dengue With Gastrointestinal Bleeding: A Case Report Highlighting Endoscopic Hemostasis.
Cureus
November 2024
Internal Medicine, Al Qassimi Hospital, Sharjah, ARE.
Dengue fever, caused by the dengue virus and transmitted by mosquitoes, poses a significant global health threat, particularly in tropical and subtropical regions. Severe cases can manifest as dengue hemorrhagic fever (DHF) or dengue shock syndrome, leading to complications such as plasma leakage, fluid accumulation, respiratory distress, severe bleeding, and organ impairment. Among these complications, gastrointestinal (GI) bleeding is particularly concerning due to its potential to rapidly deteriorate the patient's condition.
View Article and Find Full Text PDFLinking multiple serological assays to infer dengue virus infections from paired samples using mixture models.
medRxiv
December 2024
Department of Medicine, University of California, San Francisco, USA.
Dengue virus (DENV) is an increasingly important human pathogen, with already half of the globe's population living in environments with transmission potential. Since only a minority of cases are captured by direct detection methods (RT-PCR or antigen tests), serological assays play an important role in the diagnostic process. However, individual assays can suffer from low sensitivity and specificity and interpreting results from multiple assays remains challenging, particularly because interpretations from multiple assays may differ, creating uncertainty over how to generate finalized interpretations.
View Article and Find Full Text PDFThe climate emergency for rheumatologists: where do we stand?
Clin Rheumatol
December 2024
Department of Medicine, University of Otago, Wellington, New Zealand.
Climate change and pollution are a major existential threat. Healthcare contributes a noteworthy 4-6% to the total carbon footprint and 5-7% of the total greenhouse gas (GHG) emissions. Environmental pollution and modern lifestyles are also contributing to the increased prevalence of autoimmune and lifestyle-related rheumatic disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!